PARD (Poniard Pharmaceuticals) Current Accrued Expense: $1.50 Mil (As of Sep. 2011)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Poniard Pharmaceuticals Current Accrued Expense?

Poniard Pharmaceuticals PARD Current Accrued Expense is $1.50 Mil as of Sep. 2011.

Poniard Pharmaceuticals's Current Accrued Expense for the quarter that ended in Sep. 2011 was $1.50 Mil.

Poniard Pharmaceuticals's quarterly Current Accrued Expense declined from Mar. 2011 ($0.99 Mil) to Jun. 2011 ($0.93 Mil) but then increased from Jun. 2011 ($0.93 Mil) to Sep. 2011 ($1.50 Mil).

Poniard Pharmaceuticals's annual Current Accrued Expense declined from Dec. 2008 ($10.62 Mil) to Dec. 2009 ($7.68 Mil) and declined from Dec. 2009 ($7.68 Mil) to Dec. 2010 ($1.22 Mil).

Poniard Pharmaceuticals Current Accrued Expense Related Terms

Poniard Pharmaceuticals Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Poniard Pharmaceuticals's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Poniard Pharmaceuticals Current Accrued Expense Chart

Poniard Pharmaceuticals Annual Data
Trend Dec01 Dec02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.52 4.55 10.62 7.68 1.22

Poniard Pharmaceuticals Quarterly Data
Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.96 1.22 0.99 0.93 1.50

Poniard Pharmaceuticals Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $1.50 Mil mean?
Poniard Pharmaceuticals (PARD) has a Current Accrued Expense of $1.50 Mil as of Sep. 2011. Current Accrued Expense records the total amount of accrued expenses. View historical data on Poniard Pharmaceuticals and its competitors.
Is Poniard Pharmaceuticals' Current Accrued Expense too high?
Poniard Pharmaceuticals' current Current Accrued Expense is $1.50 Mil.
How does Poniard Pharmaceuticals' Current Accrued Expense compare to OBMP and NSPX?
Poniard Pharmaceuticals' Current Accrued Expense of $1.50 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Poniard Pharmaceuticals and its competitors. Poniard Pharmaceuticals's current Current Accrued Expense is $1.50 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Poniard Pharmaceuticals stock overvalued right now?
Poniard Pharmaceuticals (PARD) has a current Current Accrued Expense of $1.50 Mil. The current Current Accrued Expense is $1.50 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Poniard Pharmaceuticals (PARD), the current Current Accrued Expense is $1.50 Mil as of Sep. 2011. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Poniard Pharmaceuticals Business Description

Address 300 Elliott Avenue West, Suite 530, Seattle, CA, USA, 98119
Poniard Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of cancer therapeutics. Its product candidate is picoplatin, a new generation platinum-based cancer therapy.